CellMosaic prepares peptide–drug conjugates based on a unique conjugation strategy developed at CellMosaic. Drugs can be conjugated anywhere on the peptide (C-terminal, N-terminus, or in the middle). Usually, a single, pure bioconjugate can be obtained. The whole process can be easily tailored to a client's project. This is a fast approach and great solution for clients who want to develop peptide-based conjugates.

Advantages of CellMosaic's peptide conjugation strategy:

• Freedom to attach drug or molecule of interest at any point in the peptide.
• Other functional groups, such as OH, NH2, and SH, in the peptide will not be affected by the conjugation step.
• The conjugation strategy can easily be tweaked to couple to different categories of compounds.
• Short timeline for the development of a bioconjugation strategy.

CellMosaic offers site-specific antibody labeling and conjugation for pharmaceutical and biotech companies based on the unique conjugation strategy developed at CellMosaic. Small drugs or toxins can be conjugated to an antibody at a specific site away from the antigen binding site.

Comparison of labeling technologies:

Traditional antibody labeling technologies usually take advantage of the multiple Lys groups located in the antibody. Modification of the Lys groups changes the overall pI of the antibody and leads to higher nonspecific binding. In addition, if some of the modified or conjugated Lys residues are located on the antigen binding sites this method may produce partially active or inactive antibody conjugates that may not bind to the antigen.

Disadvantages of traditional Lys labeling technology are:

• Multiple and unpredictable labeling of antibody and a heterogeneous pool of labeled antibodies.
• Lower antigen binding corresponding to higher dosage.
• Nonspecific and inefficient binding leading to high toxicity.

Advantages of CellMosaic's site-specific labeling technology:

• Drug labeling of antibody at single or few predictable sites (manufacturing reproducibility).
• Retained antigen binding (lower dosage).
• Specific binding (efficient and safe drugs).

CellMosaic offers bioconjugation research and development services for biopharmaceutical companies devoted to antisense and siRNA-based therapeutics.

Some of the obstacles in developing oligonucleotide analogs and siRNA-based therapeutics include limited cellular uptake, poor in vivo pharmacokinetic properties, and a lack of specificity for the target tissues/cells. New studies have shown that chemically conjugated oligonucleotide analogs and siRNAs with bioactive molecules, lipids, and polymers can overcome some of these limitations.

Whether you are looking for a transport vector, such as peptides, for an oligonucleotide, or modifying oligonucleotide backbones, CellMosaic can provide the technical know-how based on years of experience in oligonucleotide research.

CellMosaic offers research and development services for bio-pharmaceutical companies that develop recombinant proteins as therapeutics.

Recombinant proteins are not very stable in vivo and high dosages are often required in clinical use. Chemical modification of recombinant proteins with water-soluble molecules may improve proteomic stability, resulting in better therapeutic effects. Recombinant proteins can also be conjugated to antibodies, drugs, and toxins for other beneficial effects.

CellMosaic's scientists have extensive experience in protein purification and modification. We can chemically modify or process your recombinant proteins for better clinical performance. We can also develop synthetic biopolymer carriers or small molecules for conjugation to recombinant proteins.